CONSULTING AGREEMENT AGREEMENT made this 2nd day of March, 2004, by and between Matthew Maguire., an individual, with offices at 6435 Manhattan Village Ave., #3l03, Orlando, FL 32835 (the "Consultant"), and CTD Holdings, Inc., a corporation with...Consulting Agreement • April 15th, 2004 • CTD Holdings Inc • Medicinal chemicals & botanical products • Florida
Contract Type FiledApril 15th, 2004 Company Industry Jurisdiction
SERIES A-1 COMMON STOCK PURCHASE WARRANT CYCLO THERAPEUTICS, INC.Cyclo Therapeutics, Inc. • January 3rd, 2023 • Biological products, (no disgnostic substances)
Company FiledJanuary 3rd, 2023 IndustryTHIS SERIES A-1 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _________________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on January 3, 2028 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Cyclo Therapeutics, Inc., a Nevada corporation (the “Company”), up to 2,608,696 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 3rd, 2023 • Cyclo Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJanuary 3rd, 2023 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of December 29, 2022, between Cyclo Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 4th, 2023 • Cyclo Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 4th, 2023 Company IndustryThis Registration Rights Agreement (this “Agreement”) is made and entered into as of May 2, 2023, by and among Cyclo Therapeutics, Inc., a Nevada corporation (the “Company”), and Rafael Holdings, Inc., a Delaware corporation (“Purchaser”).
RECITALS:Employment Agreement • July 2nd, 2001 • CTD Holdings Inc • Medicinal chemicals & botanical products • Florida
Contract Type FiledJuly 2nd, 2001 Company Industry Jurisdiction
PRE-FUNDED COMMON STOCK PURCHASE WARRANT CYCLO THERAPEUTICS, INC.Cyclo Therapeutics, Inc. • November 21st, 2022 • Industrial organic chemicals • New York
Company FiledNovember 21st, 2022 Industry JurisdictionTHIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received ___________, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Cyclo Therapeutics, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the "Agreement") entered into this 1st day of July, 2009 (the "Effective Date"), between VISTRA GROWTH PARTNERS, INC. ("ViStra"), a wholly-owned subsidiary of CTD HOLDINGS, INC. (the "Company") and LOUIS...Employment Agreement • January 19th, 2010 • CTD Holdings Inc • Industrial organic chemicals
Contract Type FiledJanuary 19th, 2010 Company Industry
PREAMBLEShare Exchange Agreement • August 16th, 2005 • CTD Holdings Inc • Medicinal chemicals & botanical products • Florida
Contract Type FiledAugust 16th, 2005 Company Industry Jurisdiction
RECITALS:Employment Agreement • December 1st, 2003 • CTD Holdings Inc • Medicinal chemicals & botanical products • Florida
Contract Type FiledDecember 1st, 2003 Company Industry Jurisdiction
CONSULTING AGREEMENT DATE: March 25, 2004 PARTIES: ALAN C. FERGUSON (the "Consultant") CTD HOLDINGS, INC., a Florida corporation (the "Company") AGREEMENTS: SECTION 1. RETENTION OF CONSULTANT 1.1 Effective Date. Effective March 25, 2004 (the...Consulting Agreement • March 26th, 2004 • CTD Holdings Inc • Medicinal chemicals & botanical products • Florida
Contract Type FiledMarch 26th, 2004 Company Industry Jurisdiction
Warrant AgentWarrant Agency Agreement • November 16th, 2020 • Cyclo Therapeutics, Inc. • Industrial organic chemicals • New York
Contract Type FiledNovember 16th, 2020 Company Industry JurisdictionWARRANT AGENCY AGREEMENT, dated as of ____, 2020 (“Agreement”), between Cyclo Therapeutics, Inc., a corporation organized under the laws of the State of Nevada (the “Company”), and VStock Transfer LLC (the “Warrant Agent”).
1,950,000 SHARES OF COMMON STOCK OF CYCLO THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • November 19th, 2021 • Cyclo Therapeutics, Inc. • Industrial organic chemicals • New York
Contract Type FiledNovember 19th, 2021 Company Industry JurisdictionThe undersigned, Cyclo Therapeutics, Inc., a company incorporated under the laws of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Cyclo Therapeutics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Maxim Group LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
COMMON STOCK PURCHASE WARRANT CYCLO THERAPEUTICS, INC.Cyclo Therapeutics, Inc. • November 21st, 2022 • Industrial organic chemicals • New York
Company FiledNovember 21st, 2022 Industry JurisdictionTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received ___________, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Charter Amendment Date (as defined below) (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the fifth anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Cyclo Therapeutics, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the "Agreement") is effective as of May 30, 2001 (the "Effective Date") by and between CTD HOLDINGS, INC., a Florida corporation (the "Company"), and C.E. RICK STRATTAN (the "Employee"). RECITALS: This...Employment Agreement • April 1st, 2002 • CTD Holdings Inc • Medicinal chemicals & botanical products • Florida
Contract Type FiledApril 1st, 2002 Company Industry Jurisdiction
COMMON STOCK PURCHASE WARRANTCTD Holdings Inc • June 4th, 2019 • Industrial organic chemicals
Company FiledJune 4th, 2019 IndustryTHIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, ___________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on November 30, 2024 (the “Termination Date”) but not thereafter, to subscribe for and purchase from ctd holdings, Inc. a Florida corporation (the “Company”), up to [______] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Warrant AgentWarrant Agency Agreement • December 11th, 2020 • Cyclo Therapeutics, Inc. • Industrial organic chemicals • New York
Contract Type FiledDecember 11th, 2020 Company Industry JurisdictionWARRANT AGENCY AGREEMENT, dated as of December 11, 2020 (“Agreement”), between Cyclo Therapeutics, Inc., a corporation organized under the laws of the State of Nevada (the “Company”), and VStock Transfer LLC (the “Warrant Agent”).
RECITALS:Employment Agreement • March 30th, 2004 • CTD Holdings Inc • Medicinal chemicals & botanical products • Florida
Contract Type FiledMarch 30th, 2004 Company Industry Jurisdiction
CYCLO THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • December 11th, 2020 • Cyclo Therapeutics, Inc. • Industrial organic chemicals • New York
Contract Type FiledDecember 11th, 2020 Company Industry JurisdictionThe undersigned, Cyclo Therapeutics, Inc., a company incorporated under the laws of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Cyclo Therapeutics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Maxim Group LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
CYCLO THERAPEUTICS, INC. UNDERWRITING AGREEMENTCyclo Therapeutics, Inc. • November 16th, 2020 • Industrial organic chemicals • New York
Company FiledNovember 16th, 2020 Industry JurisdictionThe undersigned, Cyclo Therapeutics, Inc., a company incorporated under the laws of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Cyclo Therapeutics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Maxim Group LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT CYCLO THERAPEUTICS, INC.Cyclo Therapeutics, Inc. • January 3rd, 2023 • Biological products, (no disgnostic substances)
Company FiledJanuary 3rd, 2023 IndustryTHIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on December 29, 2027 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Cyclo Therapeutics, Inc., a Nevada corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain Engagement Agreement, by and between the Company and H.C. Wainwright & Co., LLC, dated as of December 18, 2022.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 4th, 2019 • CTD Holdings Inc • Industrial organic chemicals • New York
Contract Type FiledJune 4th, 2019 Company Industry JurisdictionThis Securities Purchase Agreement (this "Agreement") is dated as of May 30, 2019, between CTD Holdings, Inc., a Florida corporation (the "Company"), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a "Purchaser" and collectively, the "Purchasers").
Natural Spirit Mushroom Enterprise Inc., 27327 NW 78th Avenue High Springs, FL 32643Cyclodextrin Technologies Development Inc • March 31st, 2000 • Medicinal chemicals & botanical products
Company FiledMarch 31st, 2000 Industry
CYCLO THERAPEUTICS, INC. COMMON STOCK EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • August 16th, 2021 • Cyclo Therapeutics, Inc. • Industrial organic chemicals • New York
Contract Type FiledAugust 16th, 2021 Company Industry JurisdictionCyclo Therapeutics, Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc., as follows:
REPRESENTATIVE COMMON STOCK PURCHASE WARRANTCyclo Therapeutics, Inc. • November 16th, 2020 • Industrial organic chemicals • New York
Company FiledNovember 16th, 2020 Industry JurisdictionTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on _____3 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Cyclo Therapeutics, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall be issued pursuant to that certain Underwriting Agreement, dated as of ____, 2020, by and between the Company and Maxim Group LLC, as representative of the several Underwriters named in Schedule A thereto (the “Underwriting Agreement”
PLACEMENT AGENCY AGREEMENT May 30, 2019Placement Agency Agreement • June 4th, 2019 • CTD Holdings Inc • Industrial organic chemicals • New York
Contract Type FiledJune 4th, 2019 Company Industry Jurisdiction
VOTING AGREEMENTVoting Agreement • September 21st, 2023 • Cyclo Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledSeptember 21st, 2023 Company Industry JurisdictionThis Voting Agreement (this “Voting Agreement”) is being delivered on September [•], 2023 by the person or persons named on the signature pages hereto (collectively, the “Holder”), as the holder of Company Shares (as defined below) of Applied Molecular Transport Inc., a Delaware corporation (the “Company”), to Cyclo Therapeutics, Inc., a Nevada corporation (“Parent”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 2nd, 2011 • CTD Holdings Inc • Industrial organic chemicals • Florida
Contract Type FiledFebruary 2nd, 2011 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (the "Agreement") is effective as of January 1, 2008, (the "Effective Date") by and between CTD HOLDINGS, INC., a Florida corporation (the "Company"), and C.E. RICK STRATTAN (the "Employee").
CYCLO THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 4th, 2023 • Cyclo Therapeutics, Inc. • Biological products, (no disgnostic substances) • Florida
Contract Type FiledMay 4th, 2023 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is made and entered into as of May 2, 2023, by and among Cyclo Therapeutics, Inc., a Nevada corporation (the “Company”), and Rafael Holdings, Inc., a Delaware corporation (“Purchaser”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 2nd, 2022 • Cyclo Therapeutics, Inc. • Industrial organic chemicals • Florida
Contract Type FiledMarch 2nd, 2022 Company Industry JurisdictionTHIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), is made as of the 28th day of February, 2022 (the “Effective Date”), by and between Cyclo Therapeutics Inc., a Nevada corporation with its principal place of business at 6714 NW 16th Street, Suite B, Gainesville, FL 32653 (together with its subsidiaries, the “Company") and Michael Lisjak (the “Executive”) (collectively, the “Parties”).
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger AgreementCyclo Therapeutics, Inc. • September 21st, 2023 • Biological products, (no disgnostic substances)
Company FiledSeptember 21st, 2023 IndustryGAINESVILLE, FL and SOUTH SAN FRANCISCO, CA – (Businesswire) – September 21, 2023 – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (Nasdaq: AMTI) (“AMT”), a biopharmaceutical company, announced today that the companies have entered into a definitive agreement (the Merger Agreement) pursuant to which AMT will merge with Cyclo Therapeutics in an all-stock transaction (the Merger). Following the closing of the Merger, the combined company will operate under the name “Cyclo Therapeutics, Inc.” and will continue trading on The Nasdaq Capital Market under the ticker symbol “CYTH”. The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1). The transaction
GUARANTY (Continuing Debt – Unlimited)CTD Holdings Inc • March 28th, 2011 • Industrial organic chemicals • Florida
Company FiledMarch 28th, 2011 Industry Jurisdiction
CYCLO THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 20th, 2023 • Cyclo Therapeutics, Inc. • Biological products, (no disgnostic substances) • Florida
Contract Type FiledOctober 20th, 2023 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is made and entered into as of October 20, 2023, by and among Cyclo Therapeutics, Inc., a Nevada corporation (the “Company”), and the investors identified on the signature pages hereto (each a “Purchaser”, and collectively, the “Purchasers”).
AGREEMENT AND PLAN OF MERGER Among Cyclo Therapeutics, Inc. Cameo Merger Sub, Inc. And Applied Molecular Transport Inc. Dated as of September 21, 2023Agreement and Plan of Merger • September 21st, 2023 • Cyclo Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledSeptember 21st, 2023 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER dated as of September 21, 2023 (this “Agreement”), is among Cyclo Therapeutics, Inc., a Nevada corporation (“Parent”), Cameo Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a direct, wholly-owned subsidiary of Parent, and Applied Molecular Transport Inc., a Delaware corporation (the “Company”).
RECITALS:Public Relations Services Agreement • May 15th, 2000 • Cyclodextrin Technologies Development Inc • Medicinal chemicals & botanical products • Florida
Contract Type FiledMay 15th, 2000 Company Industry Jurisdiction
EMPLOYMENT AGREEMENTEmployment Agreement • March 14th, 2013 • CTD Holdings Inc • Industrial organic chemicals • Florida
Contract Type FiledMarch 14th, 2013 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (the "Agreement") is effective as of January 1, 2012, (the "Effective Date") by and between NANOSONIC PRODUCTS, INC., a Florida corporation (the "Company"), and JEFFREY L. TATE, Ph.D. (the "Employee").